Devimistat

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Wednesday, September 28, 2022

September 28, 2022 - Cornerstone Pharmaceuticals, Inc. , a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613 (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer.

Key Points: 
  • September 28, 2022 - Cornerstone Pharmaceuticals, Inc. , a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613 (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer.
  • The initiation of this Phase 1 trial is an important milestone for Cornerstone and demonstrates our continued commitment to exploring the potential of devimistat as a novel pancreatic cancer treatment, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.
  • The Phase 1 trial is an open-label, dose-escalation study being conducted at the Medical College of Wisconsin in Milwaukee.
  • The combination of devimistat with chemoradiation could potentially lead to significant improvements in local control of pancreatic cancer with minimal added toxicity.

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Retrieved on: 
Wednesday, August 3, 2022

In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

Key Points: 
  • In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.
  • The Phase 1b portion of the trial enrolled 20 patients and concluded that the combination of gemcitabine and cisplatin with devimistat is well tolerated.
  • The randomized Phase 2 portion of the trial is open and accruing patients across 10 cancer centers in the U.S., targeting an enrollment of 78 patients.
  • Advanced biliary tract cancer is a rare and aggressive form of cancer with a 5-year survival rate of less than 5%.

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Retrieved on: 
Wednesday, July 6, 2022

CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Companys Scientific Advisory Board.

Key Points: 
  • CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Companys Scientific Advisory Board.
  • Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics.
  • Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism, said Sanjeev Luther, President & CEO at Cornerstone Pharmaceuticals.
  • Cornerstone Pharmaceuticals (Cornerstone) is committed to the development of therapies for rare cancers that have few to no treatment options available.

Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022

Retrieved on: 
Monday, June 27, 2022

We are excited to share updates from our open-label phase 1 study for devimistat in pancreatic cancer at ESMO, said Sanjeev Luther, President & CEO of Cornerstone Pharmaceuticals.

Key Points: 
  • We are excited to share updates from our open-label phase 1 study for devimistat in pancreatic cancer at ESMO, said Sanjeev Luther, President & CEO of Cornerstone Pharmaceuticals.
  • Im pleased to share the results of this study on devimistat for pancreatic cancer, said Angela Alistar, M.D., Medical Director of Gastrointestinal Medical Oncology at Atlantic Health System in New Jersey and principal investigator of the study.
  • The results demonstrate that treatment with devimistat is feasible, well tolerated and potentially clinically synergistic with chemotherapy for patients with pancreatic adenocarcinoma.
  • Cornerstone Pharmaceuticals (Cornerstone) is committed to the development of therapies for rare cancers that have few to no treatment options available.

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Retrieved on: 
Thursday, June 16, 2022

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 (devimistat) targeting carcinoma catabolism.

Key Points: 
  • Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 (devimistat) targeting carcinoma catabolism.
  • By suppressing the TCA hub, indispensable to many metabolic pathways, devimistat substantially reduces the effective redundancy of tumor catabolism.
  • The authors of the study note that their preclinical results indicate a clearly defined, detailed, potentially general class of approaches to improved clinical targeting of carcinoma catabolism.
  • Cornerstone Pharmaceuticals (Cornerstone) is committed to the development of therapies for rare cancers that have few to no treatment options available.

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, June 1, 2022

We are incredibly proud to have promising research findings to share in the three rare cancer areas that were focused on at ASCOs Annual Meeting, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.

Key Points: 
  • We are incredibly proud to have promising research findings to share in the three rare cancer areas that were focused on at ASCOs Annual Meeting, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.
  • Its an honor to discuss our research in pancreatic cancer with some of the brightest minds in clinical oncology at ASCO, said Dr. Philip.
  • Currently, patients who live with relapsed or refractory clear cell sarcoma (CCS) have limited treatment options, said Dr. Agulnik.
  • Cornerstone Pharmaceuticals (Cornerstone) is committed to the development of therapies for rare cancers that have few to no treatment options available.

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Retrieved on: 
Tuesday, May 24, 2022

Biliary tract cancer is considered rare and aggressive, with a large gap in effective treatment options, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.

Key Points: 
  • Biliary tract cancer is considered rare and aggressive, with a large gap in effective treatment options, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.
  • The Food and Drug Administration (FDA) has granted orphan drug designation for devimistat in seven indications in the United States, including in biliary tract cancer.
  • Devimistat is a potentially life-saving therapy, bringing hope to patients and loved ones affected by biliary tract cancer.
  • The European Medicines Agency (EMA) has granted orphan drug designation to devimistat for pancreatic cancer, acute myeloid leukemia and Burkitts lymphoma.

Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.

Retrieved on: 
Thursday, May 19, 2022

Over these last few months, the Board of Directors has worked to determine the direction of our company.

Key Points: 
  • Over these last few months, the Board of Directors has worked to determine the direction of our company.
  • Cornerstone Pharmaceuticals (Cornerstone) is committed to the development of therapies for rare cancers that have few to no treatment options available.
  • We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise.
  • In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

Retrieved on: 
Wednesday, March 2, 2022

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations.
  • As we continue to move uproleselan forward, Deepaks breadth of experience and leadership is a valuable addition to GlycoMimetics, commented Harout Semerjian, GlycoMimetics Chief Executive Officer.
  • Prior to that, he worked at ZyVersa Therapeutics (previously Variant Pharmaceuticals), where he held the position of Assistant Vice President, CMC Operations and Product Development.
  • He is the author of many peer-reviewed journal articles and the recipient of numerous awards for technical achievements.

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Retrieved on: 
Tuesday, January 18, 2022

The multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment.

Key Points: 
  • The multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment.
  • The trial is currently open through The University of Michigan Health Rogel Cancer Center as an investigator-sponsored trial.
  • The trial is also open at Fred Hutchinson Cancer Research Center and UT Southwestern Simmons Cancer Center .
  • Rafael is also launching additional sites for the trial at Northwestern University Lurie Cancer Center , UH Seidman Cancer Center , The University of Arizona Cancer Center , University of Wisconsin Carbone Cancer Center , Vanderbilt-Ingram Cancer Center , Atlantic Health System Cancer Care , and Allegheny Health Network Cancer Institute .